Con­tro­ver­sial pa­tient deaths in CAR-T study spur a class ac­tion suit against Juno

Juno con­tin­ues to feel the fall­out from its painful, and very brief, tri­al hold for its lead CAR-T JCAR015. In a new­ly filed class ac­tion suit, in­vestors say that they were pur­pose­ful­ly mis­led by Juno ex­ec­u­tives, who kept qui­et about the first sus­pi­cious pa­tient death in May.

Ac­cord­ing to the suit, the com­pa­ny was prompt­ed to tell reg­u­la­tors about the death due to a cere­bral ede­ma. But when it came to its June earn­ings an­nounce­ment, the com­pa­ny stayed silent about any deaths, stick­ing to ev­i­dence of grade 3 neu­ro­tox­i­c­i­ty. And with the com­pa­ny tout­ing its re­sults, CEO Hans Bish­op cashed out of $8.6 mil­lion in shares.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.